SCHEMBL1242340

SCHEMBL1242340

O=C(OC1CN(C(c2ccc(F)cc2)C(O)(c2cccnc2)c2cccnc2)C1)N1CCCC1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 8/20 0.54
KCNH2 Q12809 6/20 0.54
FAAH O00519 2/20 0.41
PLA2G7 Q13093 1/20 0.40
MGLL Q99685 1/20 0.40
ABHD6 Q9BV23 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HRH3 Q9Y5N1 4/20 0.37
CYP3A5 P20815 1/20 0.36
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1242312 0.86 KCNA5 (0.50) KCNA5KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL1242406 0.84 KCNA5 (0.47) KCNA5KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL1242857 0.82 KCNA5 (0.54) KCNA5KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL1242753 0.81 KCNA5 (0.50) KCNA5KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL1242863 0.81 KCNA5 (0.81) KCNA5KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL1241166 0.80 KCNA5 (0.81) KCNA5KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL1242334 0.80 KCNA5 (0.49) KCNA5KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL1242756 0.79 KCNA5 (0.58) KCNA5KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL1243184 0.78 KCNA5 (0.57) KCNA5KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL1242399 0.78 KCNA5 (0.49) KCNA5KCNH2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781635-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2012-06-13 EP disclosed
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090794-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885FAAH 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.